You are here

Article Text

Article menu
XML
Oncology
Original research
Prognostic and clinicopathological significance of pretreatment mean platelet volume in cancer: a meta-analysis
  1. Xin Chen1,2,
  2. Jing Li3,4,
  3. Xunlei Zhang5,6,
  4. Yushan Liu7,
  5. Jindong Wu1,
  6. Yangcheng Li1,
  7. Xiaopeng Cui8,
  8. Xiaohui Jiang1
  1. 1Department of General Surgery, Nantong Tumor Hospital, Nantong, China
  2. 2Department of General Surgery, Tumor Hospital Affiliated to Nantong University, Nantong, China
  3. 3Cancer Research Center Nantong, Nantong Tumor Hospital, Nantong, China
  4. 4Cancer Research Center Nantong, Nantong Tumor Hospital, Nantong Jiangsu, Nantong, China
  5. 5Department of Oncology, Nantong Tumor Hospital, Nantong, China
  6. 6Department of Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, China
  7. 7Department of Pathology, Nantong Tumor Hospital, Nantong, China
  8. 8Department of Gastrointestinal Surgery, Nantong University Affiliated Hospital, Nantong, China
  1. Correspondence to Professor Xiaohui Jiang; jxhyjl{at}163.com; Professor Xiaopeng Cui; cxp{at}ntu.edu.cn

Abstract

Objective Our study aimed to evaluate the prognostic and clinicopathological significance of pretreatment mean platelet volume (MPV) on cancer by using meta-analysis of published studies.

Design Meta-analysis.

Data sources Relevant studies available before 22 December 2019 were identified by searching MEDLINE, EMBASE.

Eligibility criteria All published studies that assessed the prognostic and clinicopathological significance of pretreatment MPV on cancer were included.

Data extraction and synthesis Studies were identified and extracted by two reviewers independently. The HR/OR and its 95% CIs of survival outcomes and clinicopathological parameters were calculated.

Results A total of 38 eligible studies (41 subsets) with 9894 patients with cancer were included in the final meta-analysis. MPV level was not significantly associated with both overall survival (HR 0.98, 95% CI 0.84 to 1.14) and disease-free survival (HR 1.22, 95% CI 0.86 to 1.73) of patients with cancer. Neither advanced nor mixed-stage tumour patients showed significant association between MPV and overall survival (HR 1.36, 95% CI 0.96 to 1.94, HR 0.90, 95% CI 0.74 to 1.09). However, high MPV had the strongest relationship with poor overall survival (HR 2.01; 95% CI 1.08 to 3.41) in gastric cancer, followed by pancreatic cancer (HR 1.54; 95% CI 1.31 to 1.82). Whereas in the subgroup using receiver operating characteristic curve method to define cut-off values, low MPV was significantly related to poor overall survival (HR 0.78, 95% CI 0.64 to 0.95). In addition, MPV had no significant association with age (OR 0.96, 95% CI 0.90 to 1.02), sex (OR 1.04, 95% CI 1.00 to 1.09), depth of cancer invasion (OR 0.90, 95% CI 0.77 to 1.04) and tumour stage (OR 0.91, 95% CI 0.78 to 1.07).

Conclusions Pretreatment MPV level is of no clearly prognostic significance in cancers and no significant association with clinicopathological parameters of patients with cancers.

  • haematology
  • oncology
  • adult oncology
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/bmjopen-2020-037614

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    Footnotes

    • XC, JL and XZ contributed equally.

    • Contributors XC and JL were involved in drafting the manuscript. XZ and YL made contributions to the concepts, acquisition and analysis of the data. JW and YL was involved in acquisition of data and preparing the figures. XJ and XC designed and revised the manuscript. All authors have read and approved the final manuscript.

    • Funding The work was supported by Youth Research Fund Project of the Health and Family Planning Commission of Nantong (QA2019028), Guiding Project of Nantong Municipal Science and Technology Plan (JCZ19110).

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement Data are available in a public, open access repository. All data for this study are publicly available and are ready for the public to download at no cost from the official websites of the PubMed and EMBASE. There is no need to have the formal permission to use data for this study. The sources and data robustness have been described in the section of ‘Methods’.